A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy
Tóm tắt
Từ khóa
Tài liệu tham khảo
Siegel R, Naishadham D, Jemal A . Cancer statistics 2012. Cancer Stat 2012; 62: 10–29.
Cooperberg MR, Broering JM, Carroll PR . Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117–1123.
Moul J . Prostate specific antigen only progression of prostate cancer. J Urol 2000; 163: 1632–1642.
Punnen S, Cooperberg MR, D’Amico A V, Karakiewicz PI, Moul JW, Scher HI et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol 2013; (e-pub ahead of print).
Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci M a, Partin AW et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 2012; 109: 32–39.
Saylor PJ, Smith MR . Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009; 181: 1998–2006.
Patel AR, Stephenson AJ . Radiation therapy for prostate cancer after prostatectomy: adjuvant or salvage? Nature reviews. Urology 2011; 8: 385–392.
Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Kevin M, Klein EA et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25: 2035–2041.
Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299: 2760–2769.
Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T et al. Early versus delayed hormonal therapy for prostate-specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004; 171: 1141–1147.
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC . Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591–1597.
Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ, Yossepowitch O, Vickers AJ et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009; 27: 4300–4305.
Abdueva D, Wing M, Schaub B, Triche T, Davicioni E . Quantitative expression profiling in formalin-fixed paraffin-embedded samples by affymetrix microarrays. J Mol Diagno 2010; 12: 409–417.
Thompson RH, Blute ML, Slezak JM, Bergstralh EJ, Leibovich BC . Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era? J Urol 2007; 178: 459–463.
Barlow WE, Ichikawa L, Rosner D, Izumi S . Analysis of case-cohort designs. J Clin Epidemiol 1999; 52: 1165–1172.
Erho N, Crisan A, Vergara I a, Mitra AP, Ghadessi M, Buerki C et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE 2013; 8: e66855.
Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H . Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001; 165: 119–125.
Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol 2013. http://linkinghub.elsevier.com/retrieve/pii/S002253471304603X. (e-pub ahead of print).
Cooperberg MR, Hilton JF, Carroll PR . The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 2011; 117: 5039–5046.
Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan A, Diblasio CJ et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2008; 23: 7005–7012.
Ihaka R, Gentleman R . R: A language for data analysis and graphics. J Comput Graph Stat 1996; 5: 299–314.
Heagerty PJ, Lumley T, Pepe MS . Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000; 56: 337–344.
Vickers AJ, Cronin AM, Elkin EB, Gonen M . Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decision Making 2008; 8: 53.
Moul JW, Bañez LL, Freedland SJ . Rising PSA in nonmetastatic prostate cancer. Oncology 2007; 21: 1436–1445.
Lin DY, Ying Z . Cox regression with incomplete covariate measurements. J Am Statist Assoc 88: 1341–1349.
Grambsch PM, Therneau TM . Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515–526.
Fine JP, Gray RJ . A proportional hazards model for the subdistribution of a competing risk. J Am Statist Assoc 1999; 94: 496–509.
Murphy RC, Kawashima A, Peller PJ . The utility of 11C-choline PET/CT for imaging prostate cancer: a pictorial guide. Am J Roentgenol 2011; 196: 1390–1398.
Ding Z, Wu C-J, Chu GC, Xiao Y, Ho D, Zhang J et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011; 470: 269–273.